Hip Pelvis.  2021 Jun;33(2):45-52. 10.5371/hp.2021.33.2.45.

The Effect of Teriparatide on the Hip: A Literature Review

• Kim K
• Won Yy
• Lee Sw
• Seo Kd

• KMID: 2525929
• DOI: http://doi.org/10.5371/hp.2021.33.2.45

Abstract

Teriparatide (TPTD) is a bone-forming agent used to treat postmenopausal osteoporosis. Since hip fractures are related to higher morbidity and mortality rates than other fractures, efficacious osteoporosis drugs for the hip are critical. We reviewed research articles reporting the efficacy of TPTD in terms of bone mineral density (BMD), fractures prevention, changes in the outer diameter, cortical thickness and porosity, post-operative periprosthetic BMD loss, and healing of typical and atypical fractures of the hip. Data meta-analyses indicated that TPTD not only increased the BMD of the proximal femur but also decreased the risk of hip fractures. Even though TPTD increases the cortical bone porosity of the proximal femur, the bone strength does not decrease as the majority of the porosity is located at the endocortex; further, it increases the outer diameter and thickens the cortical bone. TPTD stimulates bone remodeling and facilitates callus maturity and fracture healing. There have been many reports on improving the effect of TPTD on the healing of atypical fractures; therefore it is advisable to use TPTD considering the increase benefit compared to the risk.

Keyword

Parathyroid hormone; Teriparatide; Osteoporosis; Hip fractures; Hip